In vitro effects of sulbactam combinations with different antibiotic groups against clinical Acinetobacter baumannii isolates

References

• Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis. 2008;46(8):1254–63.
   PubMed Web of Science ®Google Scholar
• Dizbay M, Tunccan OG, Sezer BE, Hizel K. Nosocomial imipenem-resistant Acinetobacter baumannii infections: epidemiology and risk factors. Scand J Infect Dis. 2010;42(10):741–6.
   PubMedGoogle Scholar
• Garnacho-Montero J, Amaya-Villar R. Multiresistant Acinetobacter baumannii infections: epidemiology and management. Curr Opin Infect Dis. 2010;23(4):332–9.
   PubMed Web of Science ®Google Scholar
• Towner KJ. Acinetobacter: an old friend, but a new enemy. J Hosp Infect. 2009;73(4):355–63.
   PubMed Web of Science ®Google Scholar
• Gordon NC, Wareham DW. Multidrug-resistant Acinetobacter baumannii: mechanism of virulance and resistance. Int J Antimicrob Agents. 2010;35(3):219–26.
   PubMed Web of Science ®Google Scholar
• Coyne S, Courvalin P, Perichon B. Efflux-mediated antibiotic resistance in Acinetobacter spp. Antimicrob Agents Chemother. 2011;55(3):947–53.
   PubMed Web of Science ®Google Scholar
• Vila J, Pachon J. Acinetobacter baumannii resistant to everything: what should we do? Clin Microbiol Infect. 2011;17(7):955–6.
   PubMed Web of Science ®Google Scholar
• Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenemresistant Acinetobacter spp. J Antimicrob Chemother. 2008;61(6):1369–75.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard M7-A6, 6th ed., Wayne (PA): CLSI; 2003.
   Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, twenty-second informational supplement. M100-S22, Wayne (PA): CLSI; 2012.
   Google Scholar
• Pillai SK, Moellering RC, Eliopoulos GM. Antimicrobial combinations. In: Lorian VL. editor. Antibiotics in laboratory medicine. 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2005. p. 365–424.
   Google Scholar
• Moody J. Synergism testing: broth microdilution checkerboard and broth macrodilution methods. In: Isenberg HD, editor. Clinical microbiology procedures handbook. 2nd ed. Washington (DC): ASM Press; 2004. p. 1–28.
   Google Scholar
• Falagas ME, Karveli EA. The changing global epidemiology of Acinetobacter baumannii infections: a development with major public health implications. Clin Microbiol Infect. 2007;13(2):117–9.
   PubMed Web of Science ®Google Scholar
• Neonakisn IK, Spandidos DA, Petinaki E. Confronting multidrug-resistant Acinetobacter baumannii: a review. Int J Antimicrob Agents. 2011;37(2):102–9.
   PubMed Web of Science ®Google Scholar
• Gilad J, Carmeli Y. Treatment options for multidrug-resistant Acinetobacter species. Drugs. 2008;68(2):165–89.
   PubMed Web of Science ®Google Scholar
• Kuo LC, Lai CC, Liao CH, Hsu CK, Chang YL, Chang CY, et al.. Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome. Clin Microbiol Infect. 2007;13(2):196–8.
   PubMed Web of Science ®Google Scholar
• Michalopoulos A, Falagas ME. Treatment of Acinetobacter infections. Expert Opin Pharmacother. 2010;11(5):779–88.
   PubMed Web of Science ®Google Scholar
• Kiffer CR, Sampaio JL, Sinto S, Oplustil CP, Koga PC, Arruda AC, et al.. In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii. Diagn Microbiol Infect Dis. 2005;52(4):317–22.
   PubMed Web of Science ®Google Scholar
• Ko WC, Lee HC, Chiang SR, Yan JJ, Wu JJ, Lu CL, et al.. In vitro and in vivo activity of meropenem and sulbactam against a multidrug-resistant Acinetobacter baumannii strain. J Antimicrob Chemother. 2004;53(2):393–5.
   PubMed Web of Science ®Google Scholar
• Lee NY, Wang CL, Chuang YC, Yu WL, Lee HC, Chang CM, et al.. Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study. Pharmacotherapy. 2007;27(11):1506–11.
   PubMed Web of Science ®Google Scholar
• Wang FD, Lin ML, Lee WS, Liu CY. In vitro activities of beta-lactam antibiotics alone and in combination with sulbactam against Gram-negative bacteria. Int J Antimicrob Agents. 2004;23(6):590–5.
   PubMed Web of Science ®Google Scholar
• Aubert G, Guichard D, Vedel G. In-vitro activity of cephalosporins alone and combined with sulbactam against various strains of Acinetobacter baumannii with different antibiotic resistance profiles. J Antimicrob Chemother. 1996;37(1):155–60.
   PubMed Web of Science ®Google Scholar
• Fuchs PC, Stickel S, Anderson PH, Barry AL, Shilling S. In vitro inactivation of aminoglycosides by sulbactam, other-β-lactams, and sulbactam-β-lactam combinations. Antimicrob Agents Chemother. 1991;35(1):182–4.
   PubMed Web of Science ®Google Scholar
• Savov E, Chankova D, Vatcheva R, Dinev N. In vitro investigation of the susceptibility of Acinetobacter baumannii strains isolated from clinical specimens to ampicillin/sulbactam alone and in combination with amikacin. Int J Antimicrob Agents. 2002;20(5):390–2.
   PubMed Web of Science ®Google Scholar
• Kempf M, Djouhri-Bouktab L, Brunel JM, Raoult D, Rolain JM. Synergistic activity of sulbactam combined with colistin against colistin resistant Acinetobacter baumannii. Int J Antimicrob Agents. 2012;39(2):180–1.
   PubMed Web of Science ®Google Scholar
• Petersen PJ, Labthavikul P, Jones CH, Bradford PA. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother. 2006;57(3):573–6.
   PubMed Web of Science ®Google Scholar
• Kiratisin P, Apisarnthanarak A, Kaewdaeng S. Synergistic activities between carbapenems and other antimicrobial agents against Acinetobacter baumannii including multidrug-resistant and extensively drug-resistant isolates. Int J Antimicrob Agents. 2010;36(3):243–6.
   PubMed Web of Science ®Google Scholar
• Frimodt-Moller N. How predictive is PK/PD for antibacterial agents. Int J Antimicrob Agents. 2002;19(4):333–9.
   PubMed Web of Science ®Google Scholar
• Owens RC Jr, Shorr AF. Rational dosing of antimicrobial agents: pharmacokinetic and pharmacodynamic strategies. Am J Health Syst Pharma. 2009;66(12 Suppl 4):S23–30.
   PubMed Web of Science ®Google Scholar